Does Anthem (Elevance Health) Cover Lunesta (Eszopiclone)?

What Is Eszopiclone and Why Do Insurers Scrutinize It?

Eszopiclone is the S-enantiomer of zopiclone and belongs to the nonbenzodiazepine cyclopyrrolone class of sedative-hypnotics. The FDA approved it in December 2004 under the brand name Lunesta for the treatment of insomnia characterized by difficulty falling asleep and difficulty staying asleep in adults. The full prescribing information is available on the FDA label.

Insurers flag eszopiclone because the brand version costs roughly $140 per month at list price while generic eszopiclone costs approximately $20 per month, a 7-fold price difference for the same molecule. Anthem applies utilization management to steer members toward lower-cost generics first, which is consistent with the American Academy of Sleep Medicine (AASM) position that generic hypnotics carry equivalent efficacy profiles to branded versions for most patients. The AASM clinical practice guideline on chronic insomnia disorder assigns a conditional recommendation to eszopiclone for sleep-onset and sleep-maintenance insomnia in adults based on moderate-quality evidence.

A second reason for scrutiny is the drug's controlled-substance status. Schedule IV hypnotics receive additional formulary oversight across most major commercial carriers, including Anthem, because of abuse-potential concerns flagged in the FDA Drug Safety Communication on complex sleep behaviors.

The controlled-substance designation does not mean Anthem will automatically deny claims. It does mean the prior authorization form will ask for documented diagnoses, prior non-pharmacologic treatment (cognitive behavioral therapy for insomnia, or CBT-I), and trial durations for any previously used hypnotics.

Anthem Formulary Placement for Lunesta

On most Anthem commercial PPO and HMO formularies, brand-name Lunesta sits at Tier 3 (non-preferred brand), while generic eszopiclone occupies Tier 2 (preferred brand) or Tier 1 (preferred generic) depending on the specific plan year and market. Anthem posts formularies by plan at anthem.com/pharmacy, updated annually each January.

Because formularies change each plan year, the safest approach is to search the specific formulary document for your group number rather than relying on a prior year's tier assignment. Generic eszopiclone 1 mg, 2 mg, and 3 mg tablets are available from multiple manufacturers and are almost always covered without PA on Tier 1 or Tier 2.

The critical distinction: if your prescriber writes for brand Lunesta specifically (with "dispense as written"), Anthem will apply both the higher brand copay and the full PA/step-therapy requirement even if generic eszopiclone would otherwise be covered at a lower tier. Writing the prescription generically avoids the Tier 3 hurdle in most cases and may eliminate the PA requirement entirely on some Anthem plan variants.

Anthem Medicare Advantage formularies (the PDP component) treat eszopiclone somewhat differently. CMS Part D rules limit coverage of Schedule IV controlled substances to a 30-day supply per fill, and some Anthem Medicare Advantage plans place eszopiclone on Tier 3 or Tier 4 with a separate prior authorization that references CMS Part D excluded drug criteria.

Prior Authorization Criteria for Lunesta on Anthem

Anthem's prior authorization for eszopiclone typically requires four documented elements. First, a confirmed diagnosis of chronic insomnia disorder meeting criteria from the International Classification of Sleep Disorders, Third Edition (ICSD-3), defined as difficulty initiating or maintaining sleep at least three nights per week for at least three months with associated daytime impairment. Second, documented trial or contraindication to CBT-I. Third, step-therapy completion through at least one preferred generic sedative-hypnotic at an adequate dose for at least 28 days. Fourth, absence of clinical contraindications such as severe hepatic impairment, where the prescribing information recommends dose reduction to 1 mg.

The step-therapy agents Anthem most commonly lists as required predecessors are zolpidem immediate-release (Ambien generic, 5 to 10 mg), zolpidem extended-release (Ambien CR generic, 6.25 to 12.5 mg), trazodone (off-label, 50 to 100 mg), and low-dose doxepin (Silenor generic, 3 to 6 mg). Doxepin at 3 to 6 mg has Level A evidence from the AASM guideline for sleep-maintenance insomnia and is often the last required step before Lunesta authorization is approved.

Anthem's clinical criteria documents are not always publicly posted in full, but the company is required to provide the specific criteria to a member or prescriber upon request under the No Surprises Act and state insurance regulations. Your prescriber's office can call Anthem Provider Services (the number on the back of the member ID card) to request the exact PA criteria sheet before submitting.

PA approval timelines run 3 to 5 business days for standard reviews and 24 to 72 hours for urgent reviews when a physician certifies that the standard timeline would seriously jeopardize the member's health. The CMS UM transparency rule effective 2024 requires that Anthem (as a Medicare Advantage and Medicaid contractor) report PA approval and denial rates publicly, a regulatory shift that increases accountability for utilization management decisions.

Step Therapy: What Anthem Requires Before Approving Lunesta

Step therapy for Lunesta on Anthem commercial plans generally follows a one-to-two-step sequence. The first required step is a 28-day trial of generic zolpidem at an appropriate dose, with documentation of the reason for discontinuation, inadequate efficacy, adverse effects (most commonly next-day sedation or complex sleep behaviors), or a contraindication. The second step, on plans that require it, is a 28-day trial of either generic trazodone or generic low-dose doxepin.

The clinical rationale matters here. Zolpidem is an imidazopyridine that acts on GABA-A receptors with preferential alpha-1 subunit affinity, while eszopiclone binds both alpha-1 and alpha-2/3 subunits, a pharmacological difference thought to contribute to eszopiclone's stronger sleep-maintenance effect. Krystal et al. (Sleep, 2003, N=308) demonstrated that eszopiclone 3 mg maintained efficacy across a 6-month nightly-use trial with no tolerance development. At Week 24, patients receiving eszopiclone reported statistically significant improvements in sleep latency (P<0.001), wake time after sleep onset (P<0.001), and sleep quality ratings versus placebo. This long-duration efficacy dataset is an important document to include in a PA submission when zolpidem's efficacy waned after short-term use.

Step-therapy exemptions exist and are enforceable. Under most state step-therapy laws and Anthem's own step-therapy exception policy, a prescriber can request an exception by showing: (1) the required step-therapy drug is contraindicated or the member previously tried and failed it; (2) the required drug is expected to cause an adverse reaction based on the member's other medications or conditions; or (3) the member tried the required drug prior to enrolling with Anthem. States including New York, Texas, California, and Virginia have enacted step-therapy protection laws that require insurers to process exceptions within a defined timeframe, typically 72 hours for urgent cases.

How to Appeal an Anthem Denial of Lunesta

Anthem denies PA requests for Lunesta for two primary reasons: incomplete documentation of step therapy, or insufficient clinical justification of why generic alternatives failed. Both are correctable.

Step 1: Request the Explanation of Benefits (EOB) and denial letter. The denial letter must state the specific clinical reason and the criteria used. Anthem is required to provide the criteria upon request. If the denial cites "step therapy not completed," gather pharmacy fill records, office notes documenting adverse effects, and any objective sleep data (actigraphy or sleep diary) supporting the need for eszopiclone specifically.

Step 2: Internal appeal. File within 180 days of the denial date for commercial plans (30 days for urgent appeals). Submit the appeal with a letter of medical necessity from the prescribing physician, the Krystal 2003 six-month efficacy data, documentation of prior step-therapy agent failures, and any relevant comorbidities (hepatic disease affecting zolpidem metabolism, parasomnias with prior agents, concurrent use of CYP3A4 inducers). The AASM guideline specifically recommends eszopiclone as an option for sleep-maintenance insomnia, which strengthens a medical necessity argument.

Step 3: External/Independent Review Organization (IRO). If the internal appeal is denied, you have the right to an independent external review. Federal law (ACA Section 2719) and most state laws require this pathway for coverage denials. The IRO reviewer is a board-certified physician unaffiliated with Anthem. Win rates for sleep-disorder drug appeals at external review vary by state but average 30 to 40% in states with detailed external review reporting, such as New York's Department of Financial Services data.

Step 4: State insurance department complaint. Filing a complaint with your state's insurance commissioner creates a regulatory record and sometimes prompts Anthem to re-review the case before the IRO reaches a decision.

The framework above (EOB request, internal appeal with clinical literature, IRO, state complaint) applies to commercial Anthem plans. Medicare Advantage appeals follow a parallel CMS-governed process: redetermination by Anthem, reconsideration by a Qualified Independent Contractor (QIC), ALJ hearing, Medicare Appeals Council, and finally federal district court for amounts above the threshold.

Eszopiclone Dosing and Clinical Evidence Supporting Medical Necessity

For adults, the FDA-approved starting dose of eszopiclone is 1 mg immediately before bedtime, with dose escalation to 2 mg or 3 mg based on clinical response and tolerability. The 3 mg dose produces stronger sleep-maintenance benefits. For adults 65 and older, the recommended dose is 1 mg to 2 mg due to increased sensitivity to CNS depressants. The FDA label for eszopiclone also notes that concomitant use with CYP3A4 inhibitors (e.g., ketoconazole) requires dose limitation to 1 mg.

The Krystal 2003 trial remains the foundational long-duration efficacy study. That study enrolled 308 adults with chronic insomnia, randomized to eszopiclone 3 mg or placebo nightly for 6 months. Krystal et al. reported that eszopiclone significantly reduced subjective sleep latency by 14 minutes versus placebo and increased total sleep time by 37 minutes at Week 24. No rebound insomnia occurred during a 2-week post-treatment observation period, a clinically meaningful finding when compared to agents with known rebound profiles.

A subsequent study by Roth et al. (Sleep, 2005, N=436) examined eszopiclone in patients with comorbid generalized anxiety disorder and insomnia. That trial, indexed on PubMed, found that eszopiclone 3 mg significantly improved both Hamilton Anxiety Scale scores and sleep outcomes versus placebo at Week 10, supporting use in patients whose insomnia coexists with anxiety disorders, a common clinical picture that strengthens PA documentation.

The AASM 2017 guideline on pharmacotherapy of chronic insomnia states: "We suggest that clinicians use eszopiclone as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults. (Conditional recommendation; Moderate quality of evidence.)" The full guideline text is available via PubMed. Citing this language directly in a PA or appeal submission aligns the request with published clinical standards.

A 2022 network meta-analysis by Crescenzo et al. (Lancet, 2022, N=154 trials, 44,089 participants) ranked eszopiclone among the most efficacious pharmacological treatments for sleep maintenance, second only to lemborexant for total sleep time improvement versus placebo. That meta-analysis provides comparative effectiveness data useful in establishing medical necessity when first-line agents have failed.

Using the Manufacturer Savings Card With Anthem Coverage

Brand-name Lunesta has a manufacturer patient assistance program, but the standard commercial copay card issued by the manufacturer cannot be used with federal or state government insurance programs, including Medicaid, Medicare Part D, Medicare Advantage, and CHIP. For commercial Anthem PPO or HMO plans, the card may be usable, but this depends on the plan's coupon-stacking policies. Some self-funded employer plans explicitly exclude manufacturer copay cards under ERISA plan documents.

Because generic eszopiclone costs approximately $20 per month at cash-pay prices through GoodRx, OptimRx, or direct discount programs at major pharmacy chains, many patients find that paying out of pocket for the generic is financially more practical than navigating PA for the brand. The GoodRx pricing data for eszopiclone 3 mg consistently shows prices below $25 at major chains without insurance.

For patients who genuinely require brand Lunesta rather than generic and face high out-of-pocket costs after PA approval, the manufacturer Idorsia Pharmaceuticals operates a patient assistance program. Eligibility criteria typically require income below 400% of the federal poverty level for free drug, or demonstrated financial hardship for copay assistance.

Non-Pharmacologic and Combination Approaches That Support PA Documentation

CBT-I is the first-line treatment for chronic insomnia disorder per both the AASM 2021 position statement and the American College of Physicians clinical practice guideline. Documenting a genuine CBT-I trial in the PA submission strengthens the clinical justification for pharmacotherapy. A CBT-I trial does not require in-person sessions. Digital CBT-I programs (Sleepio, Somryst, which received FDA De Novo authorization) qualify as documented non-pharmacologic treatment in most insurer criteria. The FDA authorization for Somryst provides a citable regulatory reference showing this treatment modality exists and was attempted.

Sleep hygiene education alone does not count as CBT-I for PA purposes, because CBT-I includes specific components: sleep restriction therapy, stimulus control, cognitive restructuring, and relaxation techniques, typically over 6 to 8 sessions. A brief note in the chart stating "sleep hygiene counseling provided" is insufficient documentation and is a common reason PA submissions are returned for more information.

Polysomnography is not required for a chronic insomnia diagnosis, per ICSD-3. However, if obstructive sleep apnea (OSA) is suspected, the American Academy of Sleep Medicine recommends a sleep study before initiating hypnotics, because sedative-hypnotics may worsen apnea severity by reducing arousal responses. Documenting that OSA has been ruled out or treated lowers the probability of a secondary denial based on an underlying untreated condition.

What Anthem Members Pay Out of Pocket After PA Approval

Once prior authorization is approved for brand Lunesta on a Tier 3 benefit, typical commercial Anthem out-of-pocket costs range from $60 to $120 per month for a 30-day supply, depending on the plan's brand deductible and copay structure. After meeting the plan's annual out-of-pocket maximum, cost drops to $0 for remainder of the benefit year.

For generic eszopiclone approved at Tier 1 or Tier 2, copays typically range from $10 to $45 per month on standard commercial plans. High-deductible health plans (HDHPs) paired with HSAs apply the full negotiated price until the deductible is met, which means cost for generic eszopiclone on an HDHP may be $25 to $60 per fill early in the benefit year, still substantially below the brand list price of $140. The Kaiser Family Foundation health benefits survey reports that the average employer-sponsored HDHP deductible in 2024 was $2,757 for individual coverage, a figure relevant to counseling patients on expected annual drug costs.

Anthem's Explanation of Benefits and the Summary of Benefits and Coverage (SBC) document, both available on anthem.com and required under the ACA, disclose the exact cost-sharing structure for each tier. Reviewing the SBC before filing a PA avoids surprises about deductible application.

Prescriber Strategies for Successful Anthem PA Submissions

The single most preventable reason PA submissions fail is thin clinical documentation. A PA for eszopiclone submitted with only a diagnosis code and a prescriber signature has a high denial probability. Adding the following elements substantially increases approval rates based on standard utilization management review criteria.

Include the specific duration, dose, and reason for discontinuation of each step-therapy agent. "Patient tried zolpidem 10 mg for 6 weeks; discontinued due to next-morning grogginess interfering with driving (patient is a commercial driver)" is approvable. "Zolpidem did not work" is not.

Reference the AASM conditional recommendation for eszopiclone from the 2017 guideline and the six-month nightly efficacy data from Krystal 2003 to document that eszopiclone has a stronger long-duration evidence base than the failed alternatives for this specific patient's pattern of sleep-maintenance difficulty.

Document daytime functional impairment with specifics: occupational performance, driving safety, or cognitive testing if available. Anthem's PA criteria require evidence that insomnia is not merely subjective dissatisfaction with sleep but meets the functional impairment threshold in the ICSD-3 definition of disorder. The ICSD-3 criteria are summarized in a 2014 Sleep Medicine Reviews article that can be cited to align the diagnostic framing with the insurer's reference standard.

Submit PA requests via the Availity portal or through Anthem's electronic PA pathway. Electronic submissions have shorter processing times and create an auditable timestamp trail that matters if the case proceeds to appeal. Phone-initiated PAs are permissible but harder to document for appeal purposes.

Anthem Medicare Advantage: Special Considerations for Eszopiclone

Medicare Advantage plans administered by Anthem (marketed under various regional brand names such as Anthem MediBlue, Anthem HealthKeepers Plus, and others) follow CMS Part D formulary rules. Under Part D, Schedule IV controlled substances including eszopiclone are covered in most cases but are subject to a 30-day supply limit per fill and quantity limits.

CMS requires Medicare Advantage plan sponsors to use the five-tier formulary structure. Eszopiclone on Anthem Medicare Advantage formularies typically appears at Tier 3 (preferred brand) or Tier 4 (non-preferred drug), with varying copay structures. Tier 5 (specialty tier) applies to drugs above a CMS-defined cost threshold, which eszopiclone does not typically cross given current generic pricing.

Medicare Advantage PA appeals follow the CMS-mandated timeline: Anthem must respond to a standard PA request within 3 calendar days (not business days), and an urgent PA within 24 hours, under 42 CFR 422.568 and 422.572. These timelines are stricter than commercial plan timelines and are enforceable through CMS grievance procedures.

The Medicare Advantage and Part D Star Ratings program scores plans partly on PA approval rates and appeal overturn rates. Anthem's Medicare Advantage plans therefore have financial incentives to keep overturn rates at reasonable levels, which is useful context for members who reach the external review stage.